
SUBJECT: Changes to Publicly Funded Meningococcal Immunization Program
Date: September 1, 2026
Pages: 1 (plus attachment)
To: Primary Care Providers
From: Dr. Matthew Tenenbaum, Associate Medical Officer of Health

- **Ontario will begin using quadrivalent meningococcal vaccines (Men-C-ACYW) instead of monovalent vaccines (Men-C-C) for the routine 12-month dose.**
- **Other aspects of the meningococcal vaccination schedule remain unchanged.**
- **Men-C-ACYW will automatically be distributed once Men-C-C supply is depleted.**

The monovalent conjugate meningococcal serogroup C vaccine (Men-C-C, **Menjugate Liquid** or **NeisVac-C**) has been discontinued and will no longer be available in Canada. Ontario will transition to using quadrivalent conjugate meningococcal vaccine (Men-C-ACYW, **MenQuadfi**, **Menveo** or **Nimenrix**) in the routine childhood immunization program.

This product change is based solely on the discontinuation of Men-C-C vaccine. The risk of meningococcal disease in Ontario has not changed. Men-C-C doses are still considered protective and should be used while supply is available.

Once Men-C-C doses are depleted, Men-C-ACYW will be used for routine 12-month doses, including catch-up doses. Children who previously received Men-C-C at 12 months or older do not need to be re-vaccinated.

Healthcare providers should continue to use Men-C-C until the product expires or stock is depleted. Please do not discard usable Men-C-C before expiry. Men-C-ACYW will be available for ordering through WDG Public Health once Men-C-C stock is depleted.

Routine and High-Risk Schedule

Individuals are eligible to receive one dose of meningococcal vaccine at 12 months and a second dose in Grade 7. The transition to Men-C-ACYW for the infant program does not change eligibility for or delivery of the Grade 7 Men-C-ACYW school program. It also does not affect the high-risk meningococcal immunization program. Healthcare providers should continue to follow Ontario's publicly funded immunization schedule to determine eligibility.

Additional Resources:

1. Ministry of Health – Qs & As for Health Care Providers: Meningococcal Vaccine Transition

For more information, please contact:

Name/Title: Katrina Olson, Manager, Vaccine Preventable Diseases
Email: katrina.olson@wdgpublichealth.ca
Website: www.wdgpublichealth.ca